BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) Stock Position Reduced by Aquatic Capital Management LLC

Aquatic Capital Management LLC lessened its stake in BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX - Free Report) by 58.9% in the fourth quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor owned 55,890 shares of the biotechnology company's stock after selling 80,210 shares during the period. Aquatic Capital Management LLC's holdings in BioCryst Pharmaceuticals were worth $420,000 at the end of the most recent quarter.

Several other large investors have also recently bought and sold shares of BCRX. Vanguard Group Inc. lifted its stake in shares of BioCryst Pharmaceuticals by 7.8% in the 4th quarter. Vanguard Group Inc. now owns 21,890,422 shares of the biotechnology company's stock worth $164,616,000 after acquiring an additional 1,583,826 shares during the period. Eversept Partners LP lifted its position in BioCryst Pharmaceuticals by 269.9% in the fourth quarter. Eversept Partners LP now owns 1,980,312 shares of the biotechnology company's stock worth $14,892,000 after purchasing an additional 1,444,907 shares during the period. Hillsdale Investment Management Inc. boosted its stake in BioCryst Pharmaceuticals by 65,213.3% during the 4th quarter. Hillsdale Investment Management Inc. now owns 542,100 shares of the biotechnology company's stock valued at $4,077,000 after purchasing an additional 541,270 shares in the last quarter. Norges Bank acquired a new position in shares of BioCryst Pharmaceuticals during the 4th quarter valued at $3,947,000. Finally, Schroder Investment Management Group raised its stake in shares of BioCryst Pharmaceuticals by 523.9% in the 4th quarter. Schroder Investment Management Group now owns 522,657 shares of the biotechnology company's stock worth $3,936,000 after buying an additional 438,887 shares in the last quarter. Institutional investors and hedge funds own 85.88% of the company's stock.

BioCryst Pharmaceuticals Price Performance

BioCryst Pharmaceuticals stock traded down $0.76 during midday trading on Tuesday, reaching $10.27. The stock had a trading volume of 14,474,002 shares, compared to its average volume of 2,968,266. BioCryst Pharmaceuticals, Inc. has a twelve month low of $4.75 and a twelve month high of $11.11. The firm has a market cap of $2.15 billion, a price-to-earnings ratio of -16.84 and a beta of 1.08. The firm's fifty day simple moving average is $7.74 and its two-hundred day simple moving average is $7.83.

BioCryst Pharmaceuticals (NASDAQ:BCRX - Get Free Report) last issued its earnings results on Monday, May 5th. The biotechnology company reported $0.20 EPS for the quarter, topping the consensus estimate of ($0.07) by $0.27. The business had revenue of $145.53 million during the quarter, compared to analyst estimates of $126.83 million. During the same period last year, the business earned ($0.17) EPS. The business's quarterly revenue was up 56.8% on a year-over-year basis. As a group, sell-side analysts predict that BioCryst Pharmaceuticals, Inc. will post -0.36 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of research analysts recently issued reports on the company. HC Wainwright reaffirmed a "buy" rating and set a $30.00 target price on shares of BioCryst Pharmaceuticals in a report on Tuesday. Wedbush initiated coverage on shares of BioCryst Pharmaceuticals in a research note on Tuesday, February 25th. They issued an "outperform" rating and a $15.00 price objective on the stock. JMP Securities reissued a "market outperform" rating and set a $18.00 target price on shares of BioCryst Pharmaceuticals in a research note on Friday, January 31st. Royal Bank of Canada restated an "outperform" rating and issued a $13.00 price target (up previously from $11.00) on shares of BioCryst Pharmaceuticals in a research report on Tuesday. Finally, Cantor Fitzgerald initiated coverage on BioCryst Pharmaceuticals in a research report on Tuesday, April 29th. They set an "overweight" rating and a $20.00 price objective for the company. One equities research analyst has rated the stock with a hold rating and nine have issued a buy rating to the company's stock. According to data from MarketBeat, BioCryst Pharmaceuticals presently has an average rating of "Moderate Buy" and an average target price of $16.22.

BioCryst Pharmaceuticals Profile

BioCryst Pharmaceuticals, Inc, a biotechnology company, develops oral small-molecule and protein therapeutics to treat rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema.